248 related articles for article (PubMed ID: 32480326)
1. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Gemcioglu E; Davutoglu M; Ozdemir EE; Erden A
Mult Scler Relat Disord; 2020 Jul; 42():102196. PubMed ID: 32480326
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Novi G; Mikulska M; Briano F; Toscanini F; Tazza F; Uccelli A; Inglese M
Mult Scler Relat Disord; 2020 Jul; 42():102120. PubMed ID: 32315980
[TBL] [Abstract][Full Text] [Related]
3. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Aouba A; Baldolli A; Geffray L; Verdon R; Bergot E; Martin-Silva N; Justet A
Ann Rheum Dis; 2020 Oct; 79(10):1381-1382. PubMed ID: 32376597
[No Abstract] [Full Text] [Related]
4. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
5. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
6. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
7. Acute meningoencephalitis in a patient with COVID-19.
Chaumont H; Etienne P; Roze E; Couratier C; Roger PM; Lannuzel A
Rev Neurol (Paris); 2020 Jun; 176(6):519-521. PubMed ID: 32414534
[No Abstract] [Full Text] [Related]
8. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
9. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
10. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M
JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266
[TBL] [Abstract][Full Text] [Related]
11. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Nuño L; Novella Navarro M; Bonilla G; Franco-Gómez K; Aguado P; Peiteado D; Monjo I; Tornero C; Villalba A; Miranda-Carus ME; De Miguel E; Bogas P; Castilla-Plaza A; Bernad-Pineda M; García-Lorenzo E; Rodríguez-Araya T; Balsa A
Ann Rheum Dis; 2020 Dec; 79(12):1659-1661. PubMed ID: 32606046
[No Abstract] [Full Text] [Related]
12. Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient.
Guillan M; Villacieros-Alvarez J; Bellido S; Perez-Jorge Peremarch C; Suarez-Vega VM; Aragones-Garcia M; Cabrera-Rojo C; Fernandez-Ferro J
Thromb Res; 2020 Sep; 193():107-109. PubMed ID: 32534327
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of COVID-19 pneumonia: A report of two cases.
Ravioli S; Ochsner H; Lindner G
J Infect; 2020 Aug; 81(2):e72-e73. PubMed ID: 32389787
[No Abstract] [Full Text] [Related]
14. A case of COVID-19 infection presenting with a seizure following severe brain edema.
Kadono Y; Nakamura Y; Ogawa Y; Yamamoto S; Kajikawa R; Nakajima Y; Matsumoto M; Kishima H
Seizure; 2020 Aug; 80():53-55. PubMed ID: 32540636
[No Abstract] [Full Text] [Related]
15. Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
D'Andrea S; Berardicurti O; Berardicurti A; Felzani G; Francavilla F; Francavilla S; Giacomelli R; Barbonetti A
Spinal Cord Ser Cases; 2020 Aug; 6(1):69. PubMed ID: 32753638
[TBL] [Abstract][Full Text] [Related]
16. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China.
Liu XH; Lu SH; Chen J; Xia L; Yang ZG; Charles S; Yang Y; Lin Y; Lu HZ
Emerg Microbes Infect; 2020 Dec; 9(1):1230-1232. PubMed ID: 32515651
[No Abstract] [Full Text] [Related]
18. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Okour M; Al-Kofahi M; Austin D
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
[No Abstract] [Full Text] [Related]
19. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
